Free Trial
NYSEARCA:PBE

Invesco Biotechnology & Genome ETF (PBE) Price, Holdings, & News

$61.78 -1.52 (-2.40%)
As of 04/3/2025 04:10 PM Eastern

About Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Key Stats

Today's Range
$61.65
$62.43
50-Day Range
$61.78
$70.34
52-Week Range
$59.32
$72.84
Volume
12,058 shs
Average Volume
8,429 shs
Market Capitalization
$224.26 million
Assets Under Management
$224.98 million
Dividend Yield
0.06%
Net Expense Ratio
0.58%
Aggregate Rating
Moderate Buy

ETF Overview

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. Invesco PowerShares Capital Management LLC acts as the Fund's investment adviser.

Remove Ads

Invesco Biotechnology & Genome ETF Expenses

TypePBEHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFs
Management Fee0.50%0.57%0.56%0.51%0.53%
Other Expenses0.08%0.30%0.49%0.57%0.52%
Total Expense0.58%0.70%0.72%0.73%0.71%
Fee Waiver0.00%-0.45%-0.50%-0.66%-0.55%
Net Expense0.58%0.61%0.63%0.58%0.60%
Receive PBE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invesco Biotechnology & Genome ETF and its competitors with MarketBeat's FREE daily newsletter.

PBE ETF News Headlines

PBE Invesco Biotechnology & Genome ETF
Invesco Dynamic Biotech & Genome ETF (PBE)
Your Retirement Is Caught in the Crossfire
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
See More Headlines

PBE ETF - Frequently Asked Questions

Invesco Biotechnology & Genome ETF's stock was trading at $66.53 at the start of the year. Since then, PBE stock has decreased by 7.1% and is now trading at $61.78.
View the best growth stocks for 2025 here
.

Shares of PBE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Invesco Biotechnology & Genome ETF investors own include Micron Technology (MU), Pfizer (PFE), Devon Energy (DVN), Intel (INTC), Activision Blizzard (ATVI), NVIDIA (NVDA) and Bristol-Myers Squibb (BMY).

Fund Details

Issuer
Invesco
Fund Name
Invesco Biotechnology & Genome ETF
Tax Classification
Regulated Investment Company
Stock Exchange
NYSEARCA
Current Symbol
NYSEARCA:PBE
Inception Date
6/23/2005
Fund Manager
Peter Hubbard, Michael Jeanette, Pratik Doshi, Tony Seisser

Fund Focus

Asset Class
Equity
Benchmark
Dynamic Biotech & Genome Intellidex Index
Category
Sector
Focus
Health Care
Development Level
Developed Markets
Region
North America
Number of Holdings
31

Fund Statistics

Assets Under Management
$224.98 million
Average Daily Volume
$7,790.50
Discount/Premium
-0.06%

Administrator, Advisor and Custodian

Administrator
The Bank of New York Mellon Corporation
Advisor
Invesco Capital Management LLC
Custodian
The Bank of New York Mellon Corporation
Distributor
Invesco Distributors, Inc.
Transfer Agent
The Bank of New York Mellon Corporation
Trustee
N/A
Lead Market Maker
Citadel

Options

Optionable
N/A
Short Interest
2,100 shs

Miscellaneous

Beta
0.80
Creation Unit
10,000
Creation Fee
$500.00
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

Top 10 PBE Holdings

PBE Sector Exposure

PBE Industry Exposure


This page (NYSEARCA:PBE) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners